Nesina is owned by Takeda Pharms Usa.

Nesina contains Alogliptin Benzoate.

Nesina has a total of 12 drug patents out of which 8 drug patents have expired.

Expired drug patents of Nesina are:

• US6211205
• US6329404
• US6150383
• US6303640
• US6303661
• US7078381
• US6890898
• US7459428

Nesina was authorised for market use on 25 January, 2013.

Nesina is available in tablet;oral dosage forms.

Nesina can be used as methods of treating diabetes comprising administering a dipeptidyl peptidase inhibitor and metformin, method of treating diabetes comprising administering alogliptin, methods of treating lipid metabolism and glycometabolism disorders comprising administering an insulin sensitivity enhancer such as pioglitazone in combination with an insulin secretion enhancer, methods of modifying glucose metabolism and treating diabetes comprising administering a dipeptidyl peptidase inhibitor and one or more other therapeutic agents such as metformin, method of treating diabetes comprising administering a compound such as alogliptin, methods of reducing the side effects of active components administered to a diabetic patient comprising administering an insulin sensitivity enhancer such as pioglitazone in combination with an insulin secretion enhancer, methods of reducing the amount of active components administered to a diabetic patient comprising administering an insulin sensitivity enhancer such as pioglitazone in combination with an insulin secretion enhancer, methods of lowering elevated post prandial blood glucose levels comprising administering a dipeptidyl peptidase inhibitor, methods of treating diabetes comprising administering an insulin sensitivity enhancer such as pioglitazone in combination with an insulin secretion enhancer.

Drug patent challenges can be filed against Nesina from 25 January, 2017.

The generics of Nesina are possible to be released after 16 June, 2029.